An interventional study of Mixed Nut Blend in Inflammatory Bowel Diseases (IBD), Crohn Disease (CD) and Ulcerative Colitis (UC), sponsored by Sheba Medical Center. Completed at 1 site in Israel. Open to participants aged 10 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Sheba Medical Center · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Inflammatory Bowel Diseases with a site in Israel — 9 open to participants now, 12 under way, 5 of them phase 3. Inflammatory Bowel Diseases · Israel.
Among the 69 studies in Inflammatory Bowel Diseases with a site in Israel, this one is the 34th largest by enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2025, is one of 22 with no phase, and was the 69th registered.
1,552 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.
Browse Inflammatory Bowel Diseases studies →9 of the 69 studies in Inflammatory Bowel Diseases with a site in Israel are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Israel, United States, Canada and 4 more countries
Ages 3 wk+ · Women only
Spyre Therapeutics, Inc. · Sites in Israel, United States, Argentina and 33 more countries
Ages 18–75
Shmuel Kivity, MD · Sites in Israel
Ages 18+
Eli Lilly and Company · Sites in Israel, United States, Austria and 13 more countries
Ages 2–17
Janssen Research & Development, LLC · Sites in Israel, United States, Australia and 14 more countries
Ages 2–17
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 275 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.
This study: 10 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 20 · Phase 4 3
First in 2005; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 68 across 872 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 100 across the 51 interventional studies, 50 across the 17 observational. Of the 42 that completed or were terminated, 19 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 69 have an industry lead sponsor. The 10 most frequent:
Sheba Medical Center is the lead sponsor of 679 studies on the registry; 63 are open to participants now.
Sheba Medical Center has 5 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Inflammatory Bowel Diseases with a site in Israel that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT01266538Tel-Aviv Sourasky Medical CenterInflammatory Bowel Disease(IBD)Database | 2026-12 |
| NCT07012395Spyre Therapeutics, Inc.A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | 2027-06 |
| NCT06146816Shmuel Kivity, MDThe Assessment of Infrared Treatment for Crohn's Disease | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 69 studies in Inflammatory Bowel Diseases with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, often continue to experience disruptions in the gut microbiome and metabolism even when their disease is in clinical remission on biologic therapy. These persistent gut-level changes may contribute to disease flares over time.
Nuts are nutrient-dense foods rich in unsaturated fats, fiber, minerals, and polyphenols, and have been shown to support gut health in general and cardiometabolic populations. However, their specific effects on the gut microbiome and metabolome in people with IBD in remission have not been examined.
This proof-of-concept study investigated whether short-term, daily consumption of a standardized mixed nut blend (almonds, walnuts, and pecans) shifts the gut microbiome and metabolic signals of people with IBD toward a healthier, control-like profile.
Sixty participants: 21 healthy controls, 19 participants with Crohn's disease in remission, and 20 participants with ulcerative colitis in remission, underwent a 3-day nut-avoidance washout, followed by 10 days of consuming 30 g/day of a mixed nut blend. Fecal samples were collected on days -3, 0, 5, and 10 and analyzed for microbiome composition (16S rRNA sequencing) and metabolite profiles (untargeted LC-MS metabolomics). Participants also completed a food frequency questionnaire and a daily adherence survey.
The study aimed to characterize how a defined, single food item influences gut health signals in IBD remission, providing a foundation for larger, longer-term dietary interventions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants received a defined mixed nut blend consisting of equal weights of raw almonds, walnuts, and pecans (10 g of each per daily portion, 30 g total) for 10 consecutive days, following a 3-day nut-avoidance washout period. Portions were pre-weighed, homogenized, sealed in dedicated single-use bags labeled with the intervention day, and distributed to each participant in a coded box of 10 bags.
Dietary Supplement: Mixed Nut Blend
30 g/day of a raw mixed nut blend (10 g each of almonds, walnuts, and pecans), consumed daily for 10 days after a 3-day nut-avoidance washout. The intervention was open-label and not accompanied by any additional dietary restriction.
Change in gut microbial composition following nut supplementation in IBD participants
Paired within-subject changes in gut microbial composition in IBD participants (combined Crohn's disease and ulcerative colitis), comparing pre-intervention time points (Days -3 and 0) to during-intervention time points (Days 5 and 10). Assessed by 16S rRNA amplicon sequencing of fecal samples.
Time frame: Days -3, 0, 5, and 10
Change in fecal metabolite profile following nut supplementation in IBD participants
Paired within-subject changes in the fecal metabolite profile of IBD participants (combined Crohn's disease and ulcerative colitis), comparing pre-intervention (Day 0) to during-intervention (Days 5 and 10) time points. Assessed by untargeted LC-MS metabolomics.
Time frame: Days 0, 5, and 10
Directional shift of intervention-induced changes toward the non-IBD control profile
Whether intervention-induced changes in gut microbial and fecal metabolite profiles of IBD participants move in a direction similar to patterns observed in participants without IBD at baseline. Assessed by comparing the direction of change (effect size) of significantly altered features during the intervention against their baseline differences between IBD and non-IBD controls.
Time frame: Baseline (Days -3 and 0) and during intervention (Days 5 and 10)
Plan to share: Yes — De-identified participant-level data will be made available upon publication of the primary manuscript, including microbiome composition (16S rRNA sequencing), fecal metabolite profiles, and dietary intake data, as Supplementary Datasets. Raw 16S amplicon sequencing data have been deposited in the NCBI BioProject repository under accession number PRJNA1522179.
Time frame: Available upon publication of the primary study manuscript
Access criteria: Raw 16S sequencing data are publicly available via NCBI BioProject (PRJNA1522179). Participant-level analytical datasets will be made available as Supplementary Datasets with the published manuscript.
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Sep 2025, 6 months.
Of 283 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 6 months is below that.
Counting every sponsor, half of 297 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.